Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT02376010
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 110 participants
- Registry
-
NCT02376010
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02376010. Randomized; no masking; primary purpose prevention. Start 2015-04-02 (actual); primary completion 2018-04-01 (actual). Results posted on 2021-07-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
- Condition
- Atherosclerosis
- Intervention (Drug)
- rivaroxaban
- Intervention (Drug)
- Warfarin
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Record details
- Record id
cardio:ct-nct02376010- Content hash
d9ad9a4829e2e27f1b7764d3001808ac4979f32eeb4e5a213d3b6c5eb981a819